Isomorphic adds MSD to partner roster, and other deals
It's been a busy week for pharma partnering and licensing deals, with Isomorphic Labs – fresh from a $5 billion financing – adding MSD to its list of research alliances.
The deal focuses on a single cancer target provided by MSD, with Isomorphic tasked with identifying small-molecule drug candidates against it, using its AI-powered IsoDDE drug discovery platform to perform in silico predictions and deliver molecular designs.
MSD will be responsible for preclinical and clinical development of any candidates that emerge from the programme, and will have commercial rights if they reach the market. Financial terms of the partnership are being kept confidential, but include an upfront fee as well as milestone payments and royalties on sales.
"By leveraging the generative and predictive power of the IsoDDE to address this challenging programme, this collaboration highlights our companies' shared commitment to innovation for the benefit of patient populations with unmet needs," said Sarah Skerratt, Isomorphic's chief research officer.
MSD joins Johnson & Johnson, Novartis, and Eli Lilly among London-based Isomorphic's publicly announced R&D partners. While the value of the J&J alliance has also not been revealed, the other two included more than $80 million in upfront funding as well as milestones that could be worth around $3 billion.
Isomorphic is not short of funding, however, as its $5 billion Series C earlier this week followed a $2.1 billion second-round in May and a $600 million Series A in March 2025 that will support its efforts to move several in-house candidates into clinical testing, likely in 2027.
This week's other partnerships in brief
- Pfizer has paid $330 million upfront to China's Starna Therapeutics to claim rights to three of its in vivo CAR-T candidates for autoimmune diseases, and a non-exclusive license to its platform across immunology and inflammation (I&I) and oncology applications, outside China. The total value of the deal could be more than $2.6 billion.
- AbbVie has entered into a collaboration with DISCO Pharmaceuticals focused on bispecific therapies for solid tumours, valued at up to $2.5 billion, including $40 million in upfront fees. Cologne, Germany-based DISCO has developed a surface proteomics platform that can be used to identify new targets on the surface of cancer cells, at scale, to generate a map of the 'surfaceome'. It has also previously signed up Amgen as a partner in a $618 million deal.
- Novartis has teamed up with Taiwan's OBI Pharma on a project to develop antibody-drug conjugates (ADCs) with novel payloads, using the biotech's suite of novel linker technologies. Under the terms of the agreement, OBI will receive an upfront payment of $30 million and could get another $2 billion in development, regulatory and commercial milestone payments.
